Healthcare & Life Sciences

Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification

USPTO published patent application US20260097026A1 for the use of proton pump inhibitors including prazole compounds to inhibit calcification of aortic valves, treating aortic sclerosis and stenosis. The application was filed on October 3, 2023, with inventors Arsenii Zabirnyk, Ingvar Jarle Vaage, and Kåre-Olav Stensløkken. The invention is classified under CPC codes A61K 31/4439 and A61P 9/10.

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

mRNA, Protein Vaccine Compositions for Influenza

The USPTO published patent application US20260097112A1 by inventors Jacob Glanville et al. covering vaccine compositions comprising combinations of influenza antigens. The application discloses mRNA/LNP, recombinant protein, virus-like particle (VLP), and DNA vaccine formulations. Filing date was October 17, 2025.

Ypsomed AG Injection Device with Improved Conveying Element Patent Application

The European Patent Office published patent application EP4159257A1 for an injection device with improved conveying element, filed by Ypsomed AG. The application lists six inventors and covers IPC classifications A61M 5/20, A61M 5/24, and A61M 5/315 relating to injection mechanisms. The application is designated for validation in 28 European member states including Germany, France, the United Kingdom, Italy, and Spain.

Modified-Release Minoxidil Compositions and Methods for Hair Loss Treatment

The USPTO published patent application US20260097035A1 filed by inventor Reid Waldman on December 10, 2025, covering modified-release minoxidil compositions for treating hair loss. The application discloses pharmaceutical formulations for oral administration of modified-release minoxidil and methods of using the compositions for hair loss treatment.

Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression

USPTO published patent application US20260097224A1 disclosing a method for treating neuroplasticity-related conditions by administering a dopamine receptor agonist combined with neuroplasticity-modulating drugs prior to or simultaneously with targeted energy-based neurostimulation, repeated within one day. The preferred embodiment targets depression using transcranial magnetic stimulation. Inventors are Donald A. Vaughn and Jonathan A.S. Downar, with application number 19274159 filed July 18, 2025.

Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease

The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.

Injectable Composition For Drug Delivery Using Poly Ortho Ester Polymer

USPTO published patent application US20260096985A1 for an injectable drug delivery composition using poly ortho ester (POE) polymer. The composition includes one or more solvents and therapeutic agents, including a basic therapeutic agent, with the POE polymer having a glass transition temperature between approximately −10°C and 110°C per ASTM E1640-18. Inventors are Vijay Gyanani and Jeffrey Haley, with European Application No. 19348865 filed October 3, 2025.

ALOX15 Inhibitor Patent Application for Respiratory Disorder Treatment

The USPTO published patent application US20260097102A1 on April 9, 2026, disclosing ALOX15 inhibitors for treating respiratory disorders. Inventors Julie Horowitz and Aris Baras filed the application on October 21, 2025 (Application No. 19364245). The patent covers methods of treating respiratory disorders, identifying at-risk subjects, and detecting ALOX15 variant nucleic acids and polypeptides.

RSV Polyanhydride Nanoparticle Vaccine

The USPTO published patent application US20260096999A9 for a respiratory syncytial virus (RSV) vaccine using polyanhydride nanoparticle delivery technology. The application, filed February 17, 2022 by inventors Steven M. Varga and Kevin L. Legge, claims vaccine compositions including RSV F protein in pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles, with optional adjuvant. Patent applications are published to inform the public and allow monitoring of emerging IP positions in the pharmaceutical sector.

Cysteamine for Treatment, Mitigation and Prevention of SARS-CoV-2 Infections

USPTO published patent application US20260097007A1 for cysteamine and derivatives for treating COVID-19 and related viral infections. Inventors are Jess Thoene and Robert Gavin. The application (No. 19415604) was filed December 10, 2025, and published April 9, 2026.

Tetrahydroquinoline Compounds As Antitumor Agents

USPTO published patent application US20260097029A1 for tetrahydroquinoline compounds of Formula (I) and their salts as disruptors of the FANCM/BTR interaction, useful for hampering FANCM localization to telomeres in tumor treatment. The application (No. 19112485) was filed September 22, 2023 by inventors Sandro Cosconati, Stefano Tomassi, Salvatore Di Maro, and Hilda Amelia Pickett. CPC classifications include A61K 31/4709, A61P 35/00, and C07D 215/06.

Plasmodium Falciparum Blood Stage Inhibitor Compounds for Malaria Treatment

USPTO published patent application US20260097046A1 disclosing compounds that inhibit Plasmodium falciparum asexual blood stage parasites for malaria treatment. The compounds exhibit sub-millimolar potency against intraerythrocytic stages and are soluble for oral administration. Inventors include Alicia N. Wagner, Roger Trombley, and 8 others. Application filed December 12, 2025.

Fluoro Beta-Carboline Compounds, Bone Formation Method

USPTO published patent application US20260097041A1 for fluoro beta-carboline compounds and methods of promoting bone formation. The application (No. 19202018, filed May 8, 2025) covers compounds of Formula I and their use in orthopedic devices, periodontal devices, and treatment of renal disease, diabetes, bone loss, and cancer. Inventors include Debra Ellies, F. Scott Kimball, and Robert N. Young.

Shionogi Fused Ring GLP-1 Receptor Agonist Patent Application

The USPTO published patent application US20260097037A1 by Shionogi & Co., Ltd. on April 9, 2026, covering fused ring compounds as GLP-1 receptor agonists for pharmaceutical use. The application was filed on September 21, 2023, under application number 19112403. The compounds are represented by formulas (I) and (II), with various substituents including phenyl groups and heterocyclic rings.

Conjugates for Cancer Treatment - Patent Application US20260097117A1

USPTO published patent application US20260097117A1 for conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, useful for treating cancer. The application was filed October 2, 2025, by inventors Nathan Fishkin and Peter U. Park, with a publication date of April 9, 2026.

Metalloenzyme Inhibitor Compounds (Patent Application US20260097034A1)

USPTO published patent application US20260097034A1 for metalloenzyme inhibitor compounds. The application was filed on October 2, 2025 (Application No. 19348647) by inventors Steven Sparks, Christopher M. Yates, Sammy R. Shaver, and William J. Hoekstra. The patent covers compounds having metalloenzyme modulating activity and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes.

UV/HEV Light Filtering Compounds and Their Use

USPTO published patent application US20260098007A1 for compounds and their use in filtering ultraviolet (UV) and high-energy visible (HEV) light, invented by Micah Nelp and Anthony Young. The compounds may be used in compositions, consumer products, and packaging materials. This patent grant establishes intellectual property rights for the inventors.

COMPOUNDS AND USES THEREOF - Senolytic Compounds for Aging Treatment

The USPTO published patent application US20260097022A1 for senolytic compounds and methods for treating aging-related conditions. The application covers screening of 2,352 compounds for senolytic activity and trained neural networks to predict activity across over 800,000 molecules. Compounds disclosed bind to Bcl-2 proteins and reduce senescent cell burden. Application filed October 2, 2025; published April 9, 2026.

Bioanalytical Method Validation for Biomarker Concentrations Guidance

FDA's Center for Drug Evaluation and Research issued guidance FDA-2017-D-6821 to help sponsors validate bioanalytical methods used to evaluate biomarker concentrations in drug and biologic development programs. The guidance applies to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs). It addresses method validation for biomarker analysis in both clinical study samples and nonclinical study samples.

Determination That BILTRICIDE (Praziquantel) 600mg Tablet Was Not Withdrawn From Sale

The FDA has issued a determination that BILTRICIDE (Praziquantel) oral tablet, 600 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. This determination affects pharmaceutical manufacturers, healthcare providers, and patients who rely on this anti-parasitic medication. The notice confirms the drug remains available on the market and was not subject to removal due to regulatory safety concerns.

HRSA AIDS Drug Assistance Program Data Report Extension Request

The Health Resources and Services Administration (HRSA) is seeking public comment on extending OMB Control No. 0915-0345 for the AIDS Drug Assistance Program (ADAP) Data Report. The comment period closes on May 13, 2026. This is an administrative information collection extension request for an existing data reporting mechanism used to monitor ADAP program activities.

SAMHSA Information Collection OMB Review Request

SAMHSA, a division of HHS, has submitted an information collection request to OMB for review under the Paperwork Reduction Act. The notice announces a 30-day public comment period on proposed data collection activities related to substance abuse and mental health services programs. This is a standard administrative action to gather feedback on existing or modified information collection requirements.

HRSA Extends Funding to University of Utah for Emergency Medical Services for Children Data Center

The Health Resources and Services Administration (HRSA) has issued a Notice extending funding to the University of Utah for the Emergency Medical Services for Children Data Center (EDC). The document, published in the Federal Register on April 13, 2026, is designated as Notice document number 2026-07035, appearing at citation 91 FR 18867.

Medicare Mental Health Coverage Provider Guidelines Booklet

CMS Medicare Learning Network published a booklet (MLN1986542) providing guidelines on Medicare coverage for mental health services. The publication explains which providers are eligible to furnish treatment and outlines Medicare coverage policies for mental health care.

LaCHIP Phase V Compliance Rule Amendments, Proposed

The Louisiana Department of Health proposes amendments to LAC 50:I.Chapter 205 governing the Louisiana Children's Health Insurance Program (LaCHIP) Phase V. The amendments align state rules with federal Centers for Medicare and Medicaid Services regulation 42 CFR § 457.340(e) regarding twelve-month continuous eligibility and procedures for non-payment of premiums.

April 2026 Legislative Oversight Committee Activity

The Louisiana Department of Health announced the submission of April 2026 Legislative Oversight Committee reports regarding Medicaid Program Integrity and Fraud, Waste, and Abuse Recovery. The reports were filed with legislative oversight committees pursuant to R.S. 49:968(D)(1)(b)(c). Prior submissions are available in the archives.

Abiomed Europe Control Device for VAD Heartbeat

Abiomed Europe Control Device for VAD Heartbeat

Selective Astrocytic MAGL Inactivation for Alzheimer's Disease Treatment

USPTO published patent application US20260098268A1 for compositions and methods treating Alzheimer's disease through selective astrocytic MAGL inactivation via AAV-mediated gene silencing. Inventors: Chu Chen, Jian Zhang. Filed September 29, 2023. The invention targets neuroinflammation reduction by selectively inactivating MAGL in astrocytes rather than globally, minimizing adverse effects from neuronal 2-AG degradation disruption.

Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

siRNA Compositions Targeting CD33 Gene for Neuroinflammatory Disease Treatment

The USPTO published patent application US20260098269A1 covering single- or double-stranded interfering RNA (siRNA) molecules targeting the Siglec-5 (CD33) gene, pharmaceutical compositions containing these molecules, and methods for treating neuroinflammatory diseases including Alzheimer's disease. The application claims specific nucleoside modifications, internucleoside linkage modifications, branched siRNA configurations (di-branched, tri-branched, tetra-branched), 5′ phosphorus stabilizing moieties, hydrophobic moieties, and CNS delivery methods.

Methods for Transgenerational Genome Editing in Plants

The USPTO published patent application US20260098272A1 for methods of transgenerational genome editing in plants. The application discloses nucleic acid constructs encoding RNA-guided nucleases under constitutive promoters combined with guide RNAs for editing plant genomes across generations. Inventors include Giane Balser, Lisa Kanizay, Ramanjot Kaur, Thomas Scott Ream, Zarir Vaghchhipawala, and Chenxi Wu. The application was filed on October 6, 2025, under application number 19350752.

Multivalent Trident Aptamers for Molecular Recognition

The USPTO published patent application US20260098270A1 by McMaster University on April 9, 2026. The application covers multivalent trident aptamers comprising a branched linker molecule with 2-3 variable arms connected to a root, designed for enhanced affinity and avidity in target molecular recognition. The aptamers have applications in pharmaceutical, diagnostic, and therapeutic fields.

Method for Increasing Recombinant Protein Expression

The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.

Exercise Device for Anterior Pelvic Tilt Correction

The USPTO published patent application US20260097259A1 filed by inventors Malcolm and Kim Hairston for an exercise device designed to correct anterior pelvic tilt. The device comprises a base with upper and lower supports, a rope passing through the user's legs, and a weighted holder that creates pressure against the user's stomach during walking to aid pelvic alignment. The application was filed on July 10, 2025, under Application No. 19264979.

Bone Rasp and Graft Delivery Sheath and Related Methods for Spinal Fusion

USPTO published patent application US20260096906A1 for a bone rasp and graft delivery sheath system and related methods for multi-level spinal fusion surgery. The invention covers a delivery sheath inserted through an incision near a pedicle screw, instruments with cutting surfaces for bone decortication, and delivery of bone graft or biologic materials to prepared bone surfaces. Application No. 19349725 was filed on October 3, 2025.

Expandable Corpectomy Spacer Implant, A1, Apr 09

The USPTO published patent application US20260096903A1 filed by inventors Dylan McFarland, Matthew Bakey, Colm McLaughlin, David Leff, Samuel Petersheim, and George Howard on December 2, 2025. The application covers an expandable vertebral body replacement implant assembly for spinal surgery, featuring removable endplates, a threaded actuator, outer ring, and automatic locking mechanism.

Trapezium Implant for Hemiarthroplasty of the Trapeziometacarpal Joint

The USPTO published patent application US20260096907A1 for a trapezium implant designed for hemiarthroplasty of the thumb carpo-metacarpal joint. The invention by Mark Joseph Warburton includes a saddle-shaped articular surface, a single keel design for press-fit insertion, and an accompanying insertion guide system. Patent applications are published 18 months after filing and are subject to examination before any patent rights are granted.

Bone and Joint Surface Reconstruction, Subchondral Solutions

Bone and Joint Surface Reconstruction, Subchondral Solutions

Automated Heart Valve Manufacturing System with Robotic Suturing Fixtures

USPTO published patent application US20260098364A1 for an automated prosthetic heart valve manufacturing and suturing system. The system includes robotic fixtures that maneuver needles and target devices, with suturing arms and holders capable of rotating target devices to form sutures without human intervention. Medical device manufacturers in the cardiac/prosthetic valve space should monitor this application for potential future IP developments.

CraniUS Implant System for Combined Hard and Soft Tissue Reconstruction with Embedded Medicine Delivery Technology

USPTO published patent application US20260096901A1 by CraniUS LLC for a combined hard and soft tissue medical implant featuring an integrated reservoir, embedded pump-assisted smart technology, strategic high-profile port for subcutaneous access, and embedded catheters for delivering medication or cellular therapies. The invention is classified under CPC codes A61F 2/441, A61F 2/32, A61F 2/38, A61F 2/40, and related sub-codes. The application was filed on 2025-09-29 under application number 19343130.

Compositions and Methods for Identification of VHH Antibodies That Bind a Target Antigen

The USPTO published patent application US20260098255A1 for Broad Institute's VHH antibody identification methods. The application covers compositions and methods for identifying VHH antibodies that bind target antigens. The application (No. 19415305) was filed December 10, 2025, and published April 9, 2026.

CRISPR Methods for Treating Microbial Infections - SNIPR Biome

SNIPR Biome ApS filed USPTO patent application US20260098260A1 covering CRISPR-based methods for treating microbial infections including sepsis, septicemia, SIRS, and septic shock. The application also covers controlling microbiologically influenced corrosion and biofouling in industrial or domestic systems using CRISPR technology. Inventors include Morten Sommer, Virginia Martinez, Eric van der Helm, Jakob Krause Haaber, Ana de Santiago Torio, Christian Grøndahl, and Jasper Clube.

Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy

Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy

IL-4R and TSLP Inhibitors, Inflammatory Treatment Patent Application

USPTO published patent application US20260098100A1 covering antigen binding moieties that inhibit IL-4R and TSLP pathways for inflammatory disease treatment. The application names Miguel A. Sanjuan, Sheila Gujrathi, and Ryan P. Sullivan as inventors and was filed November 10, 2025. The disclosed invention blocks IL4-IL-4R and TSLP-TSLPR interactions, targeting the same pathways addressed by approved drugs Dupilumab and Tezepelumab.

Anti-sIL7R Antibody Therapy for Treating Autoimmune Diseases

The USPTO published patent application US20260098099A1 assigned to the Board of Regents of the University of Texas System, covering methods and compositions for anti-soluble interleukin-7 receptor (sIL7R) antibodies for treating autoimmune diseases including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The application was filed on August 10, 2025.

Anti-SIRPalpha Antibody for Tumor Treatment

USPTO published patent application US20260098102A1 by National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα monoclonal antibody that binds human SIRPα to inhibit the SIRPα/CD47 interaction for use as an anti-tumor agent. The invention is classified under C07K 16/28 and related peptide technology categories.

Anti-IL-36R Monoclonal Antibody and Use Thereof for Inflammatory Disease Treatment

USPTO published patent application US20260098101A1 from QYUNS THERAPEUTICS CO., LTD. covering an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody for inflammatory disease treatment. The application was filed on December 4, 2025. The antibody comprises six complementarity determining regions with amino acid sequences specified in the filing, and the applicant claims superior neutralizing activity compared to Spesolimab at the cellular level.

Substituted Heterocycle Fused Gamma-Carbolines Synthesis

The USPTO published patent application US20260098040A1 for improved synthesis methods of substituted heterocycle fused gamma-carbolines, filed by inventor Peng Li on April 11, 2025. The application was published April 9, 2026. The document discloses synthesis methods, intermediates, and production processes for these heterocyclic compounds. No regulatory action or compliance obligations are imposed by this publication.

GLP-1 Agonist Acid Salt Patent Application

The USPTO published patent application US20260098042A1 for a novel acid salt form of a GLP-1 receptor agonist (OAD2) invented by Haiwen HU, Li FANG, Fan HU, Xinjie ZHOU, and Fenfen CHEN. The compound is classified under CPC C07D 491/056 and may be useful in treating type 2 diabetes and metabolic disorders. The application was filed August 19, 2025, and published April 9, 2026.